יחס שווי פעילות לרווח לפני ריבית, מסים ופחת appliedtherapeutics.com (APLT)

The stability of Applied Therapeutics (APLT) relies on regulatory approval of its primary drug for the therapy of rare metabolic pathologies. Applied Therapeutics (APLT) develops innovative medicines in the US, addressing the shortage of effective treatments. This price chart on the GURU.Markets platform shows that EV/EBITDA is 0.00. A commitment to ESG principles and strict bioethics in laboratories confirm high reliability and transparency in business management.

The stability of Applied Therapeutics (APLT) relies on the capital-intensive development of orphan drugs, where massive clinical trial expenditures create a high barrier to entry. The EV/EBITDA valuation multiple relates the total enterprise value, including debt, to operating profit, allowing investors to use this chart to distinguish market volatility from actual changes in fundamental value or the degradation of the company's assets.